Immunogenomics Market Report 2025

The immunogenomics market size has grown rapidly in recent years. It will grow from $5.24 billion in 2024 to $6.09 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be linked to rising prevalence of autoimmune diseases, increasing demand for personalized medicine, greater awareness of immunogenomic testing, government funding for healthcare research, and expansion of the biotechnology and pharmaceutical sectors.

The immunogenomics market size is expected to see rapid growth in the next few years. It will grow to $11.0 billion in 2029 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be linked to wider adoption of immunogenomic-based therapies, expansion of precision medicine initiatives, increased investment in research and development, growth of healthcare infrastructure, and rising demand for diagnostic solutions. Key trends during the forecast period include advancements in sequencing and genotyping technologies, innovations in immunogenomic assays, progress in bioinformatics and data analysis, development of targeted therapies, and integration of artificial intelligence in immunogenomics.

The rising prevalence of infectious diseases is expected to drive the growth of the immunogenomics market in the near future. Infectious diseases are illnesses caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, that can spread directly or indirectly from one person to another. The increasing frequency of these diseases is largely attributed to greater global travel, which facilitates the rapid transmission of pathogens across borders. Immunogenomics aids in managing infectious diseases by providing a precise analysis of host immune responses and genetic susceptibility. This approach reduces the trial-and-error nature of treatments by identifying patient-specific immune factors, which helps improve diagnostics, vaccine development, and personalized therapeutic strategies. For example, in February 2024, the UK Health Security Agency reported a 10.7% increase in tuberculosis cases in England, with 4,850 cases in 2023 compared to 4,380 in 2022. Consequently, the growing prevalence of infectious diseases is fueling the growth of the immunogenomics market.

Leading companies in the immunogenomics market are focusing on developing advanced technologies, such as single-cell transcriptome solutions, to provide high-resolution analysis of immune cell diversity and enhance the understanding of complex immune responses. Single-cell transcriptome solutions analyze the complete set of RNA transcripts in individual cells, offering insights into gene expression patterns and cellular heterogeneity within complex tissues. For example, in October 2022, Pacific Biosciences of California Inc. partnered with the Broad Institute of MIT and Harvard, along with 10x Genomics Inc., to launch a Multiplexed Arrays Sequencing (MAS-Seq) kit. This high-throughput, cost-effective sequencing solution enables the full-length analysis of single-cell RNA transcripts, uncovering novel RNA isoforms and mutations with exceptional accuracy. The technology increases sequencing throughput by 16 times by concatenating cDNA molecules and integrates seamlessly with 10x Genomics' single-cell technology and PacBio sequencers. This solution allows researchers to explore cellular heterogeneity at the isoform level, advancing disease research and biomarker discovery.

In January 2025, Adaptive Biotechnologies Corp., a US-based biotechnology firm, partnered with NeoGenomics Laboratories Inc. to enhance advanced immunogenomic testing services. This collaboration aims to expand access to personalized minimal residual disease (MRD) monitoring for blood cancer patients, facilitating tailored treatment strategies and improving patient care through the integration of cutting-edge sequencing and diagnostic technologies. NeoGenomics Laboratories Inc. is a US-based company that specializes in immunogenomics testing services.

Major players in the immunogenomics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Illumina Inc., BGI Group, GenScript Biotech Corporation, CareDx Inc., Oxford Nanopore Technologies plc, Genewiz LLC, Adaptive Biotechnologies Corporation, GenomOncology LLC, Personalis Inc., Variantyx Inc., CD Genomics Inc., Sengenics Corporation, GeneCentric Therapeutics Inc., Immunogenomics Inc., ImmuQuad Biotechnologies Inc., Neomics Pharmaceuticals LLC, Yemaachi Biotech Ltd., and BioAnalytica Biotechnology Systems Inc.

North America was the largest region in the immunogenomics market in 2024. The regions covered in immunogenomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the immunogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Immunogenomics is a branch of genomics that examines how an individual’s genetic makeup influences the immune system’s function. It focuses on identifying genetic variations that impact immune responses, susceptibility to infections and autoimmune diseases, and the effectiveness of immunotherapies and vaccines.

The primary product types of immunogenomics include instruments, consumables, software, and services. Instruments are laboratory devices used to analyze genetic material and study the immune system, including sequencers, microarray scanners, and cell sorters. Technologies employed include next-generation sequencing, microarray, polymerase chain reaction, and others. Applications span oncology, infectious diseases, autoimmune disorders, transplantation, and more, serving hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other end users.

The immunogenomics market research report is one of a series of new reports that provides immunogenomics market statistics, including immunogenomics industry global market size, regional shares, competitors with an immunogenomics market share, detailed immunogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the immunogenomics industry. This immunogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immunogenomics market also consists of revenues earned by entities by providing services such as immune profiling, bioinformatics analysis, biomarker discovery, and immunotherapy support. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunogenomics market also includes sales of sequencing kits, reagents, microarrays, and bioinformatics tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.